Active giant cell arteritis without visual loss: when initial corticosteroid therapy does not achieve remission
Clinical scenario
This protocol addresses patients with active giant cell arteritis (GCA) who do not have acute visual loss or amaurosis fugax, and whose disease has not been adequately controlled with first-line corticosteroid therapy.
Why escalation is needed — prior therapy & unmet goals
When treatment with oral prednisone-equivalent — initiated at a high dose and tapered progressively — fails to achieve the primary target (complete absence of all clinical signs and symptoms attributable to active GCA, with normalisation of ESR and CRP), the next treatment step is indicated.
Next-line approach (partial overview)
Management at this stage involves adjunctive biologic or conventional immunosuppressant therapy used alongside a structured glucocorticoid taper — the specific agent and combination are determined by disease course, relapse pattern, and individual risk factors.
Treatment goals
The aim is sustained remission: no clinical signs or symptoms of active GCA, with normal acute phase reactants maintained for at least 6 months, and the ability to taper glucocorticoids to the defined target dose without relapse.
References
DOI: 10.1136/annrheumdis-2019-215672
- The task force recommends limiting the use of intravenous pulse GC therapy to patients with complicated GCA such as those with GCA-related visual symptoms.
- Adjunctive therapy should be used in selected patients with GCA (refractory or relapsing disease, the presence or an increased risk of GC related adverse effects or complications) using tocilizumab.
- Methotrexate may be used as an alternative.
- The treatment target is sustained remission (absence of clinical signs and symptoms of active GCA + normal acute phase reactants) plus ability to taper GCs to the specified target without relapse.
View source ↗